Abbott Laboratories $ABT Shares Sold by Natural Investments LLC

Key Points

• Natural Investments LLC has reduced its holdings in Abbott Laboratories by 8.9%, now owning 38,102 shares valued at approximately $5.18 million, making it the 15th largest position in their investment portfolio.
• Abbott Laboratories reported earnings of $1.26 per share for the last quarter, meeting analyst expectations, with a revenue of $11.14 billion, reflecting a 7.4% year-over-year increase.
• The company is set to pay a quarterly dividend of $0.59 per share on November 17th, representing an annualized yield of 1.8%.

Natural Investments LLC decreased its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 8.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,102 shares of the healthcare product maker's stock after selling 3,725 shares during the quarter. Abbott Laboratories accounts for approximately 1.3% of Natural Investments LLC's investment portfolio, making the stock its 15th largest holding. Natural Investments LLC's holdings in Abbott Laboratories were worth $5,182,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Hughes Financial Services LLC purchased a new position in Abbott Laboratories during the first quarter valued at approximately $27,000. Abound Financial LLC purchased a new position in Abbott Laboratories during the first quarter valued at approximately $28,000. Elequin Capital LP purchased a new position in Abbott Laboratories during the first quarter valued at approximately $30,000. JCIC Asset Management Inc. purchased a new position in Abbott Laboratories during the first quarter valued at approximately $32,000. Finally, Vision Financial Markets LLC purchased a new position in Abbott Laboratories during the first quarter valued at approximately $33,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of recent analyst reports. William Blair upgraded Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, July 17th. BTIG Research cut their price objective on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a research report on Friday, July 18th. Royal Bank Of Canada boosted their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a research report on Tuesday, July 15th. Morgan Stanley boosted their price objective on Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Finally, Jefferies Financial Group upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and boosted their price objective for the company from $143.00 to $145.00 in a research report on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $146.17.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT opened at $132.30 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The business's 50 day moving average price is $132.54 and its 200-day moving average price is $131.56. The firm has a market capitalization of $230.26 billion, a PE ratio of 16.58, a P/E/G ratio of 2.53 and a beta of 0.69. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.26. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business's revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories's payout ratio is 29.57%.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.46% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.